Ligand Pharmaceuticals Incorporated Common Stock Ex-distribution When Issued

LGNDV | NASDAQ | 0 Sledující

$50.00

0.00%

$0.00

Sledovat

Overview Metrics Financials

Breakdown	12/31/2024 USD	12/31/2023 USD	12/31/2022 USD	12/31/2021 USD
Total revenue	167,133 +27.28%	131,314 -33.09%	196,245 -29.19%	277,133 -
Cost of revenue	11,074 -68.40%	35,049 -33.65%	52,827 -15.04%	62,176 -
Gross profit	156,059 +62.11%	96,265 -32.88%	143,418 -33.28%	214,957 -
Operating expense	178,665 +111.88%	84,323 -39.93%	140,381 +3.17%	136,062 -
Operating income	-22,606 -289.30%	11,942 +146.83%	-25,503 -132.33%	78,895 -
Pretax Income	2,518 -96.04%	63,660 +76.78%	36,011 -23.86%	47,298 -
Tax Provision	-6,550 -166.56%	9,841 -76.13%	41,230 +500.76%	-10,288 -
Net income	-4,032 -107.73%	52,154 +1,099.31%	-5,219 -109.13%	57,138 -
EPS	-0.22 -107.28%	3.02 +1,074.19%	-0.31 -109.01%	3.44 -
Diluted EPS	-0.22 -107.48%	2.94 +1,048.39%	-0.31 -109.37%	3.31 -
Average Shares	18,290 +5.73%	17,298 +2.55%	16,868 +1.43%	16,630 -
Diluted Average Shares	18,290 +3.00%	17,757 +5.27%	16,868 -2.19%	17,246 -
EBIT	5,555 -91.36%	64,316 +70.10%	37,810 -58.82%	91,824 -
EBITDA	40,794 -59.90%	101,727 +86.97%	54,407 -59.14%	133,161 -

Soubory cookie používáme ke zlepšení prohlížení na webu.